{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:45:32Z","timestamp":1790963132271,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,6,9]],"date-time":"2005-06-09T00:00:00Z","timestamp":1118275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Paclitaxel has unique activity in angiosarcomas of the face and scalp, but its activity in angiosarcomas originating at other sites is less well defined. Paclitaxel and pegylated\u2010liposomal doxorubicin (PLD) are highly effective in Kaposi sarcoma (KS). Because of the efficacy of PLD in soft tissue sarcoma in general, and in KS in particular, coupled with potential similarities in KS and angiosarcoma, and the apparent activity of paclitaxel in angiosarcomas, the authors treated patients with angiosarcoma with either paclitaxel or PLD as initial chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>To better define the efficacy of these agents in angiosarcoma, the authors reviewed their experience with paclitaxel and PLD in patients with angiosarcoma treated between 1994 and 2004.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>They identified seven patients with angiosarcoma treated with paclitaxel, and six treated with PLD. Only one patient in the series had an angiosarcoma of the scalp. Two patients receiving paclitaxel had received previous therapy with PLD, and four of six patients treated with PLD had previously received paclitaxel. Of the eight patients treated with paclitaxel, five had major responses (three had partial responses [PR] and two had complete disease remission [CR]) and three had progressive disease (PD). Of the 6 patients who received PLD, 3 had a PR for 6, 19, and &gt;20 months, respectively, 2 had stable disease for 7 and 11 months, respectively, and 1 had PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The current study demonstrated the activity of PLD (five of six patients experienced clinical benefit) and extended the data on paclitaxel in angiosarcoma, both of the face and scalp, as well as angiosarcoma originating at other sites. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21140","type":"journal-article","created":{"date-parts":[[2005,6,9]],"date-time":"2005-06-09T17:16:40Z","timestamp":1118337400000},"page":"361-366","source":"Crossref","is-referenced-by-count":174,"title":["Paclitaxel and pegylated\u2010liposomal doxorubicin are both active in angiosarcoma"],"prefix":"10.1002","volume":"104","author":[{"given":"Keith M.","family":"Skubitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,9]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Enzinger and Weiss's soft tissue tumors","author":"Weiss SW","year":"2001"},{"key":"e_1_2_6_3_2","first-page":"1581","volume-title":"Cancer: principles and practice of oncology","author":"Brennan M","year":"2005"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lab.2004.04.005"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11586"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63696-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08270-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0.CO;2-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870815)60:4<777::AID-CNCR2820600412>3.0.CO;2-T"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-002-0066-3"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199710000-00002"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909809011697"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1876"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92654-2"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1112"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.653"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.20.1556"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2445"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018907715905"},{"key":"e_1_2_6_22_2","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene\u2010glycol coated liposomes","volume":"54","author":"Gabizon A","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04152.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.13.926"},{"key":"e_1_2_6_25_2","first-page":"97","article-title":"A phase I study of ambulatory continuous infusion chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (ciCAD) for soft tissue sarcomas","volume":"2","author":"Skubitz KM","year":"1992","journal-title":"J Infus Chemother."},{"key":"e_1_2_6_26_2","first-page":"51","article-title":"Stealth liposomal doxorubicin (SLD) delivers more doxorubicin (D)X) to AIDA\u2010related Kaposi's sarcoma (AIDS\u2010KS) lesions than to normal skin","volume":"13","author":"Northfelt DW","year":"1994","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120016412"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00050-8"},{"key":"e_1_2_6_29_2","first-page":"485","article-title":"Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG)","volume":"20","author":"Toma S","year":"2000","journal-title":"Anticancer Res."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931115)72:10<2963::AID-CNCR2820721017>3.0.CO;2-W"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.1997.2050612.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197208)30:2<562::AID-CNCR2820300237>3.0.CO;2-V"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70237-3"},{"key":"e_1_2_6_34_2","first-page":"257","volume-title":"Stealth liposomes","author":"Northfelt DW","year":"1995"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(03)90586-6"},{"key":"e_1_2_6_36_2","first-page":"1038","article-title":"Phase I and pharmacokinetic study of ABI\u2010007, a cremophor\u2010free, protein\u2010stabilized, nanoparticle formulation of paclitaxel","volume":"8","author":"Ibrahim NK","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1996.tb00138.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04726.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320000221"},{"key":"e_1_2_6_40_2","first-page":"1187","article-title":"Regression of metastatic angiosarcoma of the skin after systemic treatment with liposome\u2010encapsulated doxorubicin and interferon\u2010alpha","volume":"140","author":"Jackel A","year":"1999","journal-title":"Br J Dermatol."},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1053\/clon.1999.9046"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2004.tb00681.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051610"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.050"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10602"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3483"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.043"},{"key":"e_1_2_6_48_2","first-page":"1977","article-title":"Navelbine shows activity in previously treated sarcoma patients: Phase II results form MGH\/Dana\u2010Farber\/Partner's Cancer Care Study","volume":"17","author":"Fidias P","year":"1998","journal-title":"Proc Am Soc Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21140","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:51:47Z","timestamp":1760295107000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,9]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,7,15]]}},"alternative-id":["10.1002\/cncr.21140"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21140","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,9]]}}}